Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadoxetate disodium

Next Previous
Drug Profile

Gadoxetate disodium

Alternative Names: BAY-86-4873; EOB Primovist; Eovist; Gadolinium EOB DTPA; Gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic-acid; Gadolinium-ethoxybenzyl-DTPA; Gadoxetic acid; Gadoxetic-acid-disodium; Gd-EOB-DTPA; Primovist; SH-L-569B; ZK 139834

Latest Information Update: 20 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts General Hospital
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Acetic acids; Gadolinium-containing contrast agents; Organometallic compounds; Polyamines; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver disorders

Most Recent Events

  • 01 Apr 2017 Discontinued - Phase-III for Liver disorders (Diagnosis, In infants) in USA (IV), because not listed on Bayer pipeline, April 2017
  • 01 Feb 2015 Phase-III clinical trials in Liver disorders (Diagnosis, In infants) in USA (IV)
  • 06 Feb 2014 Bayer HealthCare Pharmaceuticals plans a phase III trial for Liver disorders (diagnosis, in infants) in USA (NCT02084628)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top